Here are five things to know.
1. The FDA approved Imfinzi to treat patients with inoperable, midstage non-small cell lung cancer that has not metastasized throughout the body.
2. The drug, which inhibits tumors’ ability to hide from the immune system, represents the first immunotherapy drug approved for this use.
3. The agency previously approved the drug to treat a form of bladder cancer.
4. In a recent clinical trial involving 713 patients, Imfinzi prevented cancer progression for 16.8 months, compared to just 5.6 months for the placebo.
5. The approval opens up a multibillion market for AstraZeneca, as most of its competitors offer treatments for more advanced or metastatic forms of lung cancer.
More articles on supply chain:
Amazon pushes to become a major hospital supplier: 7 things to know
White House advisers propose fast-tracking reviews of brand-name drugs to lower costs: 6 things to know
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.